Interactive risk calculator for predicting toxicities
in patients with advanced Gastro-Intestinal Stromal Tumors (GIST)
treated with imatinib mesylate

The provided software implements the risk models published in the paper:
Martine Van Glabbeke, Jaap Verweij, Paolo G. Casali, John Simes, Axel Le Cesne, Peter Reichard, Rolf Issels, Ian R. Judson, Allan T. van Oosterom, Jean-Yves Blay. Predicting toxicities for patients with advanced gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sacoma Group and the Australian Gastro-Intestinal Trials Group.

European Journal of Cancer 42 (2006) 2277-2285

It allows the user to estimate the probability of experiencing

  • edema (CTC grade 2+),
  • lethargy (CTC grade 2+),
  • skin rash (CTC grade 2+),
  • nausea (CTC grade 2+),
  • diarrhea (CTC grade 2+),
  • anemia(CTC grade 3+)
  • neutropenia (CTC grade 3+)
  • for individual GIST patients treated with imatinib mesylate,
    at doses ranging from 400 mg/day to 800 mg/day.

Estimations are based on the intended daily dose and 8 factors:

  • Age
  • Sex
  • Performance status at treatment start
  • Prior chemotherapy (N/Y)
  • Largest diameter of the largest lesion
  • Identified gastro-intestinal origin of the tumor (N/Y)
  • Hemoglobin level at treatment start
  • Neutrophil count at treatment start

Version available as Excel spread sheet
Compact version available for handheld computers

Software programmed by Martine Van Glabbeke,
EORTC Data Center.

Download the calculator